Should You Buy Bristol Myers Squibb Stock Right Now for the Yield Alone?

Bristol Myers Squibb has risen nearly 35% since September 2025 and trades at just under 10x forward earnings with a forward dividend yield near 4%. The company faces major patent-expiry risks, including U.S. exclusivity losses for Eliquis and Opdivo in 2028; analysts forecast EPS declining to $6.56 next year from $6.95. Management is pursuing cost cuts and smaller acquisitions in cardiovascular, immunology, and oncology, while a roughly 40% forward payout ratio supports the article's view that the dividend is sustainable.

Analysis

BMY’s equity case is not primarily a dividend-duration trade; it is a credibility trade on whether non-legacy franchises can replace lost gross profit before the U.S. exclusivity roll-offs. The market will likely tolerate a multi-year revenue trough if management demonstrates that new-product growth, pricing resilience, and operating-cost reductions offset the decline in high-margin legacy products. Conversely, modest EPS beats driven only by expense reductions should not command a durable multiple re-rating because they do not solve the post-2028 earnings-power question.

The near-term setup is balanced after the recent rerating: consensus still has declining earnings power, but the low multiple leaves room for upside if launch trajectories exceed expectations. The relevant 1-3 month catalysts are quarterly net-sales growth for newer cardiovascular, immunology, and oncology assets; changes in 2027-28 consensus estimates matter more than the reported-quarter EPS print. Investors should scrutinize acquired-asset revenue, milestone obligations, R&D intensity, and net debt/interest expense rather than accepting portfolio-building claims at face value.

A non-obvious risk is that the European loss of exclusivity may be an imperfect template for U.S. erosion: U.S. formulary dynamics, biosimilar adoption, and Medicare negotiation exposure can produce a sharper gross-to-net and volume reset than modeled. That makes BMY vulnerable to multiple compression if management preserves the dividend through incremental leverage or reduced pipeline investment. AZN is a useful relative benchmark: if BMY’s new-product growth fails to close the gap with large-cap oncology peers, capital is likely to remain concentrated in proven growth platforms despite BMY’s higher income yield.

Contrarianly, the downside may be overstated if the market is valuing BMY as a static runoff asset while its pipeline and acquired portfolio generate visible 2029 earnings support. That thesis requires evidence, not yield coverage alone: upward revisions to outer-year revenue estimates and sustained growth in non-legacy sales are the falsification tests. Without those revisions, the stock can remain optically cheap for years.

Key Decisions for Investors

• Maintain a watch-to-buy stance on BMY rather than chase the recent move; initiate a long only after the next results show new-product sales growth sufficient to lift 2027-28 consensus revenue or EPS estimates. Target a 6-12 month re-rating if outer-year estimates stabilize; exit if management cuts long-term revenue targets, net debt rises unexpectedly, or U.S. loss-of-exclusivity assumptions worsen.
• For healthcare exposure, use a 6-12 month quality pair: long BMY / short an equal-dollar basket of broad pharma beta such as XPH only if BMY’s relative valuation discount remains wide after evidence of estimate stabilization. This isolates company-specific execution, but should be avoided if the read-through is sector-wide drug-pricing pressure.
• Set an earnings alert around three items: non-legacy product growth, revised 2028 revenue commentary, and cash deployment after dividends and business-development spending. A beat driven principally by cost cuts or one-time items is a sell-the-rally signal rather than confirmation of the recovery thesis.
• Do not underwrite the dividend as the primary margin of safety until free-cash-flow conversion, acquisition-related cash commitments, and debt reduction are confirmed. If payout coverage deteriorates while buybacks or acquisitions continue, reduce exposure even if the headline yield rises.